REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1

Abstract

Administration of daclizumab in addition to dual immunosuppression therapy significantly reduced biopsy-proven acute rejection after renal transplantation, improved patient survival, and did not add to the toxicity of the immunosuppressive regimen.